The Phase 3 trial investigating fenebrutinib for Relapsing Multiple Sclerosis (RMS) completed its primary data collection on 2025-09-05. This study, comparing fenebrutinib to teriflunomide, aims to evaluate the efficacy and safety of the drug in adult participants with RMS.
Background
Fenebrutinib is being investigated as a potential treatment for Relapsing Multiple Sclerosis (RMS). RMS is a chronic inflammatory demyelinating disease of the central nervous system.
Trial design
The study, identified as NCT04586023, is a Phase 3 trial. It enrolled 751 adult participants diagnosed with Relapsing Multiple Sclerosis (RMS). The trial is designed to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide. Participants were randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. The study's primary objectives include assessing disability progression and relapse rate.
What this means
The primary completion of this Phase 3 trial signifies a key milestone in the development of fenebrutinib for Relapsing Multiple Sclerosis. Once the double-blind treatment phase results are disclosed, the sponsor will determine the initiation of an open-label extension phase. The data collected will be crucial for evaluating fenebrutinib's potential as a new therapeutic option for RMS patients.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04586023, titled "Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)," was posted on 2025-09-05 on clinicaltrials.gov.